Immucell (ICCC) Gross Margin (2010 - 2026)
Immucell's (ICCC) quarterly Gross Margin came in at 38.16% in Q4 2025, up 163.0% YoY from 14.51% in Q4 2024, and down 11.08% on a QoQ basis from 42.92% in Q3 2025.
Immucell (ICCC) Gross Margin (2010 - 2026) Analysis & Trends
Immucell (ICCC) has 16 years of Gross Margin data on file, last reported at 38.16% in Q4 2025.
- Quarterly Gross Margin rose 163.0% year-over-year to 38.16% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 41.4% (up 373.0% YoY) and the FY2025 annual result came in at 41.4%, up 1143.0% from the prior year.
- Gross Margin fell to 38.16% in Q4 2025, from 42.92% in the prior quarter.
- In the past five years, Gross Margin ranged from a high of 2043.01% in Q2 2024 to a low of 8.73% in Q1 2023.
- A 5-year average of 142.32% and a median of 39.01% in 2021 frame the typical range for Gross Margin.
- Annual changes were most pronounced in 2024 — Gross Margin surged 201346 bps — and 2025, when it sank 199929 bps.
- Tracing ICCC's Gross Margin over 5 years: stood at 47.04% in 2021, then tumbled by 46 bps to 25.37% in 2022, then declined by 7 bps to 23.48% in 2023, then jumped by 56 bps to 36.53% in 2024, then grew by 4 bps to 38.16% in 2025.
- The last three Gross Margin figures came in at 38.16% (Q4 2025), 42.92% (Q3 2025), and 43.72% (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 85.33% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 91.59% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 90.43% |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 35.86% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 89.76% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 76.90% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 63.27% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 84.20% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Immucell | 91.19 Mn | 82.33 Mn | 2.44 Mn | 33.92% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 33.92% |
| Dec 31, 2025 | 38.16% |
| Sep 30, 2025 | 42.92% |
| Jun 30, 2025 | 43.72% |
| Mar 31, 2025 | 41.58% |
| Dec 31, 2024 | 36.53% |
| Sep 30, 2024 | 26.34% |
| Jun 30, 2024 | 2,043.01% |
| Mar 31, 2024 | 31.63% |
| Sep 30, 2023 | 23.48% |
| Jun 30, 2023 | 29.55% |
| Mar 31, 2023 | 8.73% |
| Dec 31, 2022 | 25.37% |
| Sep 30, 2022 | 38.49% |
| Jun 30, 2022 | 44.22% |
| Mar 31, 2022 | 51.72% |
| Dec 31, 2021 | 47.04% |
| Sep 30, 2021 | 46.96% |
| Jun 30, 2021 | 45.67% |
| Mar 31, 2021 | 39.01% |